In preclinical studies, VYN202 achieved consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic models Phase 1a SAD/MAD trial expected to start this quarter May 06, 2024 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, t

Treatment with IMG-007, the only clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb), led to rapid, marked, and durable improvement of skin signs in patients with atopic dermatitis (AD). Overall, IMG-007 was well-tolerated, without any reports of pyrexia or chills. IMG-007 is also being evaluated for the treatment of alopecia areata (AA). Final results are anticipated in Q3 2024. May 06, 2024 -- Inmagene Biopharmaceuticals ("Inmagene" or the “Company”), a clinical-stage biotechnolog

5月7日，舶望制药宣布其BW-01针对重度高甘油三酯血症的2期临床试验已于2024年4月29日完成首例受试者给药。BW-01是舶望制药自主研发的一款心血管siRNA（小干扰核酸药物）新药。 siRNA药物是近年来崭露头角的新技术药物，具有可成药靶点多、药效强、安全性好、给药频率低的优势，且适应症领域广泛，涵盖心血管疾病、罕见病、神经性疾病、病毒肝炎、眼科疾病、肿瘤等，已成为全球范围内极具发展潜力的前沿医药领域之一。 舶望制药成立于2021年，是一家处于临床阶段的生物技术公司，致力于开发新一代siRNA药物，为全球患者提供更好的治疗手段。2023年11月，舶望制药宣布完成了3亿元人民币A+轮融资，本轮融资由国投招商领投，华盖资本、元希海河基金、老股东三一创新投资跟投。 在过去近三年的时间里，舶望制药建立了包括多款siRNA候选药物的产品管线，涵盖广泛的适应症。目前舶望制药已有5个siRNA药物进入临床试验阶段。 值得一提的是，2024年1月，舶望制药宣布已与诺华（Novartis）达成了多个RNAi项目许可及战略合作协议。根据协议，舶望制药将从诺华获得1.85亿美元的首付款，以及总潜在交

May 06, 2024 -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA

Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD May 6, 2024 – Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD). This recently launched program has reached the first step with the identification of 50 targets that have the potential to provide better

Gossamer Bio和Chiesi Farmaceutici今日宣布，双方已达成全球合作与许可协议，共同开发和商业化seralutinib，用于治疗肺动脉高压（PAH）以及间质性肺病相关肺动脉高压（PH-ILD）。合作数额可超过4.8亿美元。 Seralutinib是一种专门用于治疗PAH的受体酪氨酸激酶抑制剂，能够阻断导致PAH的炎症、增殖和纤维化。Seralutinib为干燥细粉吸入剂，并使用小型手持装置进行给药。这种干燥细粉吸入剂的配方旨在使药物能够深入到肺部病变部位。 在名为TORREY的2期临床试验中，接受治疗24周后，seralutinib组患者的肺血管阻力相比于安慰剂组患者平均降低了14%（p=0.0310）。在症状更严重的一部分PAH患者中，肺血管阻力甚至降低了21%（p=0.0427），并且6分钟步行距离较安慰剂组患者增加了37米。此外，相比于安慰剂组患者，seralutinib组患者的心脏功能障碍生物标志物血清N末端脑钠肽前体（NT-proBNP）也有显著降低。 Gossamer公司在2023年启动了3期临床试验PROSERA。Gossamer和Chiesi计划

May 06, 2024 -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (LSE/STO/Nasdaq: AZN) completed the additional equity investment of $140M in Cellectis, as previously announced by Cellectis on November 1 and 15, 2023 (the “Addit

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that scientific presentations with new data on its antibiotic ceftobiprole (Zevtera®) have been presented at ESCMID Global 2024, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 27 to 30, 2024 in Barcelona, Spain. Dr. Marc Engel

近日，安进(Amgen)发布了2024年第一季度收益报告，总收入增长了22%，达到74亿美元。 得益于25%的销量增长推动，产品整体销售额增长了22%，包括Repatha、Tezspire、Evenity、Blincyto和Tavneos等在内的10款产品均实现了至少两位数的销量增长，分别收入5.17亿美元（+33%）、1.73亿美元（+80%）、3.42亿美元（+35%）、2.44亿美元（+26%）、0.51亿美元（nm）。 财报中，安进表示其减肥产品MariTide（AMG133）目前正在进行一项II期研究，预计2024年底公布数据。并且，MariTide的临床二期试验的中期观察让该公司“非常受鼓舞”，该公司计划迅速推进三期临床，并提高实验药物的生产能力。 受此消息的影响，安进的股票大涨近12%。 该公司还准备在今年晚些时候进行另一项专门的II期试验，测试MariTide对肥胖和非肥胖糖尿病患者的治疗效果。MariTide是一款first-in-class的双特异性抗体多肽偶联物，针对肥胖适应症，只需每4周皮下注射1次。该药物抑制葡萄糖依赖性促胰岛素释放多肽受体（GIPR，又称胃抑

May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. The primary endpoint of mean re